tiprankstipranks
Trending News
More News >

EyePoint completes enrollment in Phase 3 LUGANO trial of DURAVYU

EyePoint (EYPT) Pharmaceuticals announced it has enrolled and randomized over 400 patients in the Phase 3 LUGANO pivotal trial of DURAVYU for the treatment of wet age-related macular degeneration exceeding its enrollment target. The seven-month enrollment for LUGANO represents one of the fastest enrolling Phase 3 pivotal trials for wet AMD to date.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue